Valbenazine Tosylate
Brand Formulations & Prices
1 brands sorted by unit price
📖 Official Clinical Monograph
DGDA Approved Prescribing GuidelinesTardivex is indicated for the treatment of adults with Tardive Dyskinesia.
The initial dose is 40 mg once daily. After one week, increase the dose to the recommended dose of 80 mg once daily. Continuation of 40 mg once daily may be considered for some patients. Administer it orally with or without food.
Somnolence, QT Prolongation
Tardivex can cause somnolence. May impair the patient's ability to drive or operate hazardous machinery. Tardivex may prolong the QT interval. For patients who are CYP2D6-poor metabolizers or are taking a strong CYP2D6 inhibitor, dose reduction may be necessary. Avoid use in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. No dosage adjustment is necessary for patients with mild to moderate renal impairment. Use is not recommended in patients with severe renal impairment.
Valbenazine and its active metabolites bind to and inhibit vesicular monoamine transporter 2 (VMAT2) with high selectivity with no significant binding to VMAT1. This prevents the reuptake and storage of monoamine neurotransmitters noradrenaline, dopamine, and serotonin in synaptic vesicles making them vulnerable to metabolism by cytosolic enzymes. The presynaptic release of monoamine neurotransmitters is decreased due to the lack of vesicles with packaged neurotransmitters ready for release into the synapse. Neither valbenazine nor its active metabolite exhibits significant off-target binding at dopamine, serotonin, or adrenaline receptors.